Advertisement

Drugs & Therapy Perspectives

, Volume 23, Issue 3, pp 15–19 | Cite as

The treatment of lupus nephritis in children involves corticosteroids and cytotoxic agents

Disease Management
  • 40 Downloads

References

  1. 1.
    Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs 2006; 66(9): 1191–207PubMedCrossRefGoogle Scholar
  2. 2.
    Hejaili FF, Moist LM, Clark WF. Treatment of lupus nephritis. Drugs 2003; 63(3): 257–74PubMedCrossRefGoogle Scholar
  3. 3.
    Lehman TJA, Mouradian JA. Systemic lupus erythematosus. In: Holliday M, Barratt M, Avner ED, editors. Pediatric nephrology. 4th ed. Baltimore (MD): Williams and Wilkins, 1999Google Scholar
  4. 4.
    Dimitrijevic J, Dukanovic L, Kovacevic Z, et al. Lupus nephritis: histopathologic features, classification and histologic scoring in renal biopsy. Vojnosanit Pregl 2002 Nov–Dec; 59(6 Suppl.): 21–31PubMedGoogle Scholar
  5. 5.
    Barron KS, Person DA, Brewer EJ, et al. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 1982; 101: 137–41PubMedCrossRefGoogle Scholar
  6. 6.
    Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113: 249–54PubMedCrossRefGoogle Scholar
  7. 7.
    Ilowite NT. Premature atherosclerosis in systemic lupus erythematosus. J Rheumatol Suppl 2000 Apr; 58: 15–9PubMedGoogle Scholar
  8. 8.
    Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17(5): 550–7PubMedCrossRefGoogle Scholar
  9. 9.
    Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29(2): 193–9PubMedCrossRefGoogle Scholar
  10. 10.
    Lehman TJ, Sherry DD, Wagner-Weiner L, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989 Jun; 114(6): 1055–60PubMedCrossRefGoogle Scholar
  11. 11.
    Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136(2): 243–7PubMedCrossRefGoogle Scholar
  12. 12.
    British national formulary. No. 52. London: The Pharmaceutical Press, 2006 SepGoogle Scholar
  13. 13.
    Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004; 63(3): 321–3PubMedCrossRefGoogle Scholar
  14. 14.
    Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50(8): 2580–9PubMedCrossRefGoogle Scholar
  15. 15.
    Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52(10): 3168–74PubMedCrossRefGoogle Scholar
  16. 16.
    Buratti S, Szer S, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001 Sep; 28(9): 2103–8PubMedGoogle Scholar
  17. 17.
    Fu LW, Yang LY, Chan WP, et al. Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephrtitis with heavy proteinuria. Br J Rheumatol 1998; 37: 217–21PubMedCrossRefGoogle Scholar
  18. 18.
    Kuiper-Geertsma DG, Derksen RHWM. Newer drugs for the treatment of lupus nephritis. Drugs 2003;63(2): 167–80PubMedCrossRefGoogle Scholar
  19. 19.
    Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus nephritis. J Nephrol 2003; 16: 787–91PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations